Trovagene closes acquisition of CLIA laboratory assets
Wednesday, February 8, 2012
Trovagene, a developer of trans-renal molecular diagnostics based in San Diego, Calif., has closed its acquisition of MultiGEN Diagnostics’ clinical laboratory assets. Trovagene previously announced the execution of the asset acquisition agreement on Jan. 6, 2012.
MultiGEN is a molecular diagnostics company focused on DNA sequence based identification services having IP protected technologies.